$1.24
-0.04-3.13%
Last update: Oct 23, 9:29 AM
BioVie Inc (BIVI) Stock Price, Quote, News & History
BIVINASDAQ
BioVie reported Phase 2 ADDRESS-LC trial results evaluating bezisterim for Long COVID, showing significant subgroup improvements.
You can purchase shares of BioVie (NASDAQ:BIVI) through any online brokerage.
Other companies in BioVie’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
BioVie has a consensus price target of $400.00.
The stock price for BioVie (NASDAQ: BIVI) is $1.24 last updated October 23, 2026 at 9:29 AM EDT.
There are no upcoming dividends for BioVie.
BioVie does not have any upcoming earnings scheduled.
There is no upcoming split for BioVie.
BioVie is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and...
